Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Department of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Sci Rep. 2021 Feb 9;11(1):3394. doi: 10.1038/s41598-020-77736-1.
In IgA nephropathy (IgAN), IgA1 molecules are characterized by galactose deficiency in O-glycans. Here, we investigated the association between urinary glycosylation profile measured by 45 lectins at baseline and renal prognosis in 142 patients with IgAN. The primary outcome was estimated glomerular filtration rate (eGFR) decline (> 4 mL/min/1.73 m/year), or eGFR ≥ 30% decline from baseline, or initiation of renal replacement therapies within 3 years. During follow-up (3.4 years, median), 26 patients reached the renal outcome (Group P), while 116 patients were with good renal outcome (Group G). Multivariate logistic regression analyses revealed that lectin binding signals of Erythrina cristagalli lectin (ECA) (odds ratio [OR] 2.84, 95% confidence interval [CI] 1.11-7.28) and Narcissus pseudonarcissus lectin (NPA) (OR 2.32, 95% CI 1.11-4.85) adjusted by age, sex, eGFR, and urinary protein were significantly associated with the outcome, and they recognize Gal(β1-4)GlcNAc and high-mannose including Man(α1-6)Man, respectively. The addition of two lectin-binding glycan signals to the interstitial fibrosis/tubular atrophy score further improved the model fitness (Akaike's information criterion) and incremental predictive abilities (c-index, net reclassification improvement, and integrated discrimination improvement). Urinary N-glycan profiling by lectin array is useful in the prediction of IgAN prognosis, since ECA and NPA recognize the intermediate glycans during N-glycosylation of various glycoproteins.
在 IgA 肾病 (IgAN) 中,IgA1 分子的 O-聚糖中特征性地缺乏半乳糖。在此,我们研究了 142 例 IgAN 患者基线时通过 45 种凝集素测量的尿糖基化谱与肾脏预后之间的关系。主要结局是估计肾小球滤过率 (eGFR) 下降 (>4 mL/min/1.73 m/year),或 eGFR 从基线下降≥30%,或在 3 年内开始肾脏替代治疗。在随访期间 (3.4 年,中位数),26 例患者达到肾脏结局 (P 组),而 116 例患者具有良好的肾脏结局 (G 组)。多变量逻辑回归分析显示,荆豆凝集素 (ECA) (比值比 [OR] 2.84,95%置信区间 [CI] 1.11-7.28) 和水仙凝集素 (NPA) (OR 2.32,95% CI 1.11-4.85) 的结合信号与结局显著相关,并且它们分别识别 Gal(β1-4)GlcNAc 和高甘露糖,包括 Man(α1-6)Man。将两种凝集素结合聚糖信号添加到间质纤维化/肾小管萎缩评分中,进一步提高了模型拟合度 (Akaike 信息准则) 和增量预测能力 (c 指数、净重新分类改善和综合判别改善)。通过凝集素阵列进行尿 N-糖组学分析可用于预测 IgAN 预后,因为 ECA 和 NPA 识别各种糖蛋白 N-糖基化过程中的中间聚糖。